Posting of Shareholder Circular

RNS Number : 0341K

Circassia Pharmaceuticals Plc

10 December 2018

 

CIRCASSIA PHARMACEUTICALS PLC

POSTING OF SHAREHOLDER CIRCULAR

Oxford, UK - 10 December 2018: Circassia Pharmaceuticals plc ("Circassia" or "the Company") (LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces that further to the announcement earlier today, a Circular has been published and will be posted to shareholders today in relation to the proposed cancellation of ordinary shares from the Official List and Admission to trading on AIM. The Circular contains the notice convening the General Meeting to be held at the offices of Circassia Pharmaceuticals plc, Northbrook House, Robert Robinson Avenue, The Oxford Science Park, Oxford, Oxfordshire, OX4 4GA, United Kingdom at 12 midday on 4 January 2019.

A copy of the Circular will shortly be available on the Company's website at www.circassia.com.

Enquiries

Circassia
Steve Harris, Chief Executive Officer	Tel: [phone]
Julien Cotta, Chief Financial Officer
Rob Budge, Corporate Communications
Peel Hunt
James Steel / Dr. Christopher Golden	Tel: [phone]
Numis Securities
James Black / Freddie Barnfield	Tel: [phone]
FTI Consulting
Simon Conway / Mo Noonan	Tel: [phone]

About Circassia

Circassia is a world-class specialty pharmaceutical business focused on respiratory disease.  Circassia sells its novel, market-leading NIOX® asthma management products directly to specialists in the United States, United Kingdom and Germany, and in a wide range of other countries through its network of partners.  In 2017, the Company established a commercial collaboration with AstraZeneca in the United States in which it promotes the chronic obstructive pulmonary disease (COPD) treatment Tudorza® and has the commercial rights to NDA-stage COPD product Duaklir®.  For more information please visit www.circassia.com.

 

END

 

 

CIRURVBRWSAUAAA